慢性阻塞性肺疾病生物学标志物的研究进展被引量：13

Progress of biomarkers in Chronic obstructive pulmonary disease

导出

摘要慢性阻塞性疾病（chronic obstructive pulmonary disease，COPD）是大气中有害颗粒和有害气体引起的肺部慢性炎症进而引起肺部结构重塑的一种疾病，其特征为不完全可逆的气流受限，慢性缺氧和肺功能减退。流行病学资料显示COPD已位居全球死亡原因的第四位，世界卫生组织（WHO）预测至2020年COPD将成为世界疾病经济负担的第五位。

作者张永红谢新明李满祥

机构地区西安交通大学第二附属医院呼吸内科

出处《中华肺部疾病杂志（电子版）》 CAS 2013年第3期78-82,共5页 Chinese Journal of Lung Diseases(Electronic Edition)

关键词肺疾病慢性阻塞性生物标志物临床意义

分类号 R563 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献42

1冯恩志,杨生岳,闫自强,王绍林,贺巍,张瑛,殷和,陈宗茹,刘睿年.诱导痰中白介素-8和白介素-10与高原慢性阻塞性肺疾病急性加重期合并慢性肺心病发病的关系及其干预的研究[J].中华肺部疾病杂志（电子版）,2012,5(5):14-17. 被引量：8
2吴文彬,陈昌枝.慢性阻塞性肺疾病急性加重期患者血糖血脂的表达特征[J].中华肺部疾病杂志（电子版）,2012,5(5):21-25. 被引量：19
3Chapman KR, Mannino OM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease [J] . Eur Respir J, 2006, 27 (I) : 188-207.
4Vestbo J, Edwards LD, Scanlon PO, et al, Changes in forced expiratory volume in 1 second over time in COPD [J] . N Engl J Med, 2011 , 365(13): 1184-1192.
5Chung KF. Cytokines in chronic obstructive pulmonary disease [J] . Eur Respir J Suppl , 2001 , 34: 50s-59s.
6Sorensen GL, Hjelmborg N, Kyvik KO, et al. Genetic and environmental influences of surfactant protein 0 serum levels [J] . Am J Physiol Lung Cell Mol Physiol, 2006, 290(5): Ll010-Ll017.
7Lapperre TS, Snoeck-Stroband JB, Gosman MM, et at. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial [ J ]. Ann Intern Med, 2009,151(8): 517-527.
8He ZY, Ou LM, Zhang JQ, et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease [ J ]. Respiration, 2010, 80(6): 445452.
9Bathoorn E, Liesker JJ, Postma OS, et al. Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation [J] . Int J Chron Obstruct Pulmon Dis, 2009, 4: 101- 109.
10Kersul AL, Iglesias A, Rios A, et ol. Molecular mechanisms of ioflammtion during exacerbations of chronic obstructive pulmonary disease [ J ] . Arch Bronconeumol, 2011,47(4): 176-183.

二级参考文献39

1刘韵蝉,赵兰,梅元英.慢性阻塞性肺疾病患者脂质代谢研究[J].贵阳医学院学报,2001,26(1):34-35. 被引量：9
2杨晓巍.慢性阻塞性肺疾病急性加重抗菌治疗的新思维[J].医学综述,2006,12(4):237-239. 被引量：35
3钟小宁,郭韶梅.慢性支气管炎与肺气肿大鼠肺血管炎症的实验研究[J].中华结核和呼吸杂志,2006,29(7):435-439. 被引量：22
4慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量：8251
5赵华昌,李晓萍,张倩.慢性阻塞性肺疾病与血脂关系的临床探讨[J].现代预防医学,2007,34(6):1194-1195. 被引量：11
6Barbera J A,Blanco I.Pulmonary hypertension in patients chronicObstructive pulmonary disease advances in pathophysiology and man-agement[J].Drugs,2009,69(9):1153-1171.
7Grasser M,Lentz A,Lichota J,et al.The arabidopsis genome encodesstrutturally and functionally diverse HMGB-type proteins[J].J Mol Biol,2006,358(3):654-664.
8Yamada S,Maruyama I.HMGB1,a novel inflammatory cytokine[J].Clin Chim Acta,2007,375(1/2):36-42.
9Shu Z,Wei L,Mary F,et al.High mobility group box 1 protein as apotential drug target for infection-and injury-elicited inflammation[J].Inflamm Allergy Drug Targets,2010,9(1):60-72.
10Wang H,Bloom O,Zhang M,et al.HMGB1 as a late mediator of en-dotoxin lethality in mice[J].Science,1999,285(5425):248-251.